WO2004060891A1 - Enantiomere (-) du tenatoprazole et son application en therapeutique - Google Patents
Enantiomere (-) du tenatoprazole et son application en therapeutique Download PDFInfo
- Publication number
- WO2004060891A1 WO2004060891A1 PCT/FR2003/003746 FR0303746W WO2004060891A1 WO 2004060891 A1 WO2004060891 A1 WO 2004060891A1 FR 0303746 W FR0303746 W FR 0303746W WO 2004060891 A1 WO2004060891 A1 WO 2004060891A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tenatoprazole
- enantiomer
- pharmaceutically acceptable
- substantially free
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Definitions
- the present invention relates to tenatoprazole, and more particularly an enantiomer of tenatoprazole, a process for its preparation, as well as its use in human or veterinary therapy.
- Tenatoprazole i.e. 5-methoxy-2- [[((4-metho-xy-3, 5-dimethyl-2-pyridyl) methyl] sulfinyl] imidazo [4, 5-b] pyri- dine, is described in patent EP 254,588.
- the first known derivative of the proton pump inhibitor series is omeprazole, described in patent EP 005,129, which has inhibitory properties for gastric acid secretion, and is widely used as an anti-ulcer in human therapy.
- omeprazole In addition to omeprazole, other proton pump inhibitors are well known and mention may be made in particular of rabeprazole, pantoprazole and lansoprazole, all of which have a structural analogy, and which belong to the group of pyridinyl-methyl- sulfinyl-benzimidazoles. These compounds are sulfur oxides having an asymmetry at the level of the sulfur atom and are therefore generally present in the form of a racemic mixture of two enantiomers.
- omeprazole for example, application WO 01.28558 describes a stable liquid formulation obtained in forming in situ the sodium or potassium salts in solution in polyethylene glycol, by the action of a hydroxide on one omeprazole.
- the drug thus formulated can be used in the usual indications of proton pump inhibitors.
- tenatoprazole has an asymmetric structure and can therefore be in the form of the racemic mixture or its enantiomers. Thus, it can exist in the form of its two enantiomers having the configurations R and S, or (+) or (-), respectively.
- a subject of the present invention is therefore the (-) configuration enantiomer of tenatoprazole, and its use in human or veterinary therapy.
- a subject of the invention is also a pharmaceutical composition comprising the (-) enantiomer of tenatoprazole combined with one or more pharmaceutically acceptable excipients and carriers.
- the invention also relates to a pharmaceutical composition comprising (-) -tenatoprazole in combination with one or more antibiotics.
- a subject of the invention is also the use of the (-) enantiomer of tenatoprazole in the manufacture of a medicament for the treatment of digestive pathologies where an inhibition of acid secretion must be intense and prolonged for the treatment of symptoms and gastroesophageal reflux lesions, digestive bleeding resistant to other proton pump inhibitors, as well as for the treatment of these diseases in multi-drug patients.
- a subject of the invention is also the use of the (-) enantiomer of tenatoprazole in the manufacture of a medicament providing a significant improvement in wound healing as well as an increase in the speed of normalization of the histological modifications of gastric lesions in animal or man, and therefore a sharp decrease in recurrences of esophagitis.
- a further subject of the invention is the use of the (-) enantiomer of tenatoprazole for the manufacture of a medicament having improved pharmacokinetic properties allowing a dosage of a single medicament intake per day in the relevant indications, as indicated below, in particular for the eradication of Helicobacter pylori in the treatment of duodenal ulcers, which require two taken, morning and evening, with other proton pump inhibitors.
- the (-) enantiomer of tenatoprazole can be used in the form of a salt, in particular an alkali or alkaline earth metal salt, and for example in the form of a sodium, potassium, lithium, magnesium or calcium salt.
- a salt in particular an alkali or alkaline earth metal salt, and for example in the form of a sodium, potassium, lithium, magnesium or calcium salt.
- These salts can be obtained from the (-) enantiomer of the previously isolated tenatoprazole, by salification reaction according to a usual method of the technique, for example by action of basic mineral reagents comprising alkaline or alkaline counter-ions earth.
- the (-) enantiomer of tenatoprazole corresponds to (-) - 5-methoxy-2- [[(4-methoxy-3, 5-dimethyl-2-pyridyl) methyl] sufinyl] imidazo [4, 5- b] pyridine, and can be represented by the following general formula:
- the (-) enantiomer of tenatoprazole can be obtained enantioselective under good conditions of yield and purity, by enantioselective oxidation of the corresponding sulfide in the presence of a specific catalyst based on vanadium.
- a specific catalyst based on vanadium based on vanadium.
- the sulfide used as starting material is a known product which can be prepared by various methods described in the literature, and for example by the methods described in patents EP 254,588 and EP 103.553.
- the oxidant used in the process of the invention is preferably a peroxide, for example hydrogen peroxide. According to an advantageous embodiment, hydrogen peroxide at high concentration, for example greater than 30%, is used.
- the catalyst can be chosen from catalysts such as an oxo-vanadium V complex and for example vanadium acetylacetonate. Such catalysts are commercially available.
- a ligand such as a Schiff base derived from a substituted salicylic aldehyde and a chiral amino alcohol is preferably used in combination with the catalyst.
- a very particularly preferred ligand is 2,4-di-tert-butyl- ⁇ - [1 --- hydroxymethyl-2-methyl-propylimino) -methyl] -phenol.
- the reaction can be carried out in a solvent, in a neutral or weakly basic medium, for example in methanol, tetrahydrofuran, dichloromethane, acetonitrile or toluene.
- the base used can be a tertiary amine such as pyridine, di-isopropylethylamine or triethylamine.
- the oxidation reaction is easily carried out cold or at room temperature.
- the (-) enantiomer of tenatoprazole of the present invention can be readily obtained in optically pure form by the above process.
- optically pure form is meant that the (-) enantiomer is substantially free of (+) enantiomer or includes only traces thereof. If appropriate, base salification is then carried out in an appropriate solvent, to form a salt, in particular an alkali or alkaline earth metal salt.
- This shape can be determined by optical rotation measurements according to the usual techniques. For example, a 0.25% solution of the desired enantiomer (50 g of sample per 20 ml of solvent) dissolved in DMF or in acetonitrile can be prepared using a polarimeter of the commonly used type (Jobin Yvon).
- the optical rotation angle of (-) -tenatoprazole is levorotatory in dimethylformamide and in acetonitrile, and its melting point is 127-130 ° C (decomposition).
- the (-) enantiomer of tenatoprazole can also be obtained in optically pure form by well known techniques, using an appropriate separation method, for example by preparative column chromatography, such as chiral chromatography or HPLC.
- the principle of the chiral chromatography method is based on the difference in affinity between the enantiomers (+) and (-) and the chiral selector of the stationary phase. This method makes it possible to separate the enantiomers with a good yield.
- the racemic mixture which can be used as starting material can be obtained by known methods, for example according to the method described in patent EP 254,588.
- it can be prepared by treating with an oxidizing agent, such as a perbenzoic acid, the corresponding sulfide originating from the condensation of a thiol and a pyridine, preferably in the presence of a base such as potassium hydroxide in a suitable solvent, for example ethanol, hot.
- the (+) isomer remains pharmacologically active. It increases the pH by 49% (p ⁇ 0.01) and decreases the acidity by 55% (p ⁇ 0.01) compared to the control group, while the effect of the (+) isomer is not more meaningful.
- the (-) isomer of tenatoprazole differs significantly from other proton pump inhibitors by its pharmacokinetic properties, as shown by the studies described below. This characteristic is essential because it makes it possible to make available to the practitioner a medicament specifically adapted to the effective treatment of specific pathologies.
- Vmax is the maximum metabolic rate, measured in pmol / min per pmol of cytochrome.
- Vmax (-) is the value of Vmax for the (-) enantiomer of tenatoprazole.
- the (-) enantiomer is mainly metabolized by the cytochrome CYP3A4, which can compensate for a deficiency or blockage of the cytochrome CYP2C19.
- the (+) enantiomer is metabolized by two pathways, mainly CYP2C19, and to a lesser extent CYP2A4.
- a pharmacokinetic study was carried out to assess the difference in pharmacokinetic characteristics between the (-) isomer of the invention and the (+) isomer.
- This study was carried out on Caucasian subjects after acute and repeated administration (7 days) of tenatoprazole. It was then found, after 7 days of treatment, that the Plasma concentration of the (-) isomer changes linearly with dose, as does AUC, which is predictive of the subject's gastric pH, and therefore of drug activity. On the contrary, the evolution of the plasma concentration of the (+) isomer is not linear, and therefore does not allow to predict the efficacy and tolerance of the drug. In addition, the variability of pharmacokinetic parameters between subjects is significantly lower with the (-) isomer compared to the (+) isomer. In another study, it was shown that the elimination half-life of the (+) isomer in slow metabolizing subjects (deficient in CYP 2C19 activity) is approximately 4 times longer than that of the isomer. (-) as shown in the following table.
- the (-) enantiomer offers much better predictability of its action, which also makes it possible to predict and limit the risks of drug interaction when the patient is polymedicated.
- the overall conclusion of the above studies is that the (-) enantiomer of tenatoprazole has better efficacy and better tolerance, which avoids the risk of side reactions.
- the isolation of the (-) enantiomer made it possible to determine a pharmacokinetic profile different from that of the racemic, in particular an average plasma half-life of between 10 and 12 hours approximately for the (-) enantiomer for doses from 10 mg to 80 mg. Conversely, we know that the racemic has an average plasma half-life of around 7 hours in this range of doses.
- the (-) enantiomer of tenatoprazole is also suitable for the treatment of Zollinger-Ellison syndrome and other acid hypersecretion syndromes, and the treatment of atypical and esophageal symptoms of gastroesophageal reflux disease, digestive hemorrhage resistant to other pump inhibitors. protons, as well as for the treatment of these diseases in polymedicated patients, in particular in patients receiving treatments involving the administration of several drugs, and more particularly elderly patients, in order to avoid incidents linked to an interaction drug.
- the (-) enantiomer of tenatoprazole can also be used, preferably in combination with one or more antibiotics, in the treatment of ulcers in the event of infection by Helicobacter pylori, in particular for the eradication of Helicobacter pylori to promote healing of the duodenal ulcer and to prevent any recurrence.
- Barrett and Zollinger-Ellison and gastroesophageal reflux, digestive hemorrhages can be administered in the usual forms adapted to the chosen mode of administration, for example by oral or parenteral route, preferably by oral or intravenous route .
- enantiomer salt (-) of tenatoprazole can be chosen, for example, from sodium, potassium, lithium, magnesium or calcium salts.
- an appropriate formulation of tablets containing 30 mg of the (-) isomer of tenatoprazole combined with pharmaceutically acceptable carriers and excipients, at least one of which confers on the formulation of gastro-resistant properties, is indicated below. below:
- gastric-resistant enteric capsule formulation capsule containing acetophthalate derivatives, or a polyvinylpyrrolidone, or acrylic resins
- a gastric-resistant enteric capsule formulation capsule containing acetophthalate derivatives, or a polyvinylpyrrolidone, or acrylic resins
- 40 mg of (-) isomer of tenatoprazole is indicated below:
- the dosage is determined by the practitioner depending on the patient's condition and the severity of the condition. It is generally between 10 and 120 mg, preferably between
- 10 and 80 mg, (-) enantiomer of tenatoprazole per day can be administered at a dose of 1 to 2 unit doses, for example tablets, each containing 10 to 80 mg, preferably 15 or 20 to 40 or 60 mg, of active ingredient per day. for a period of time which can be between 4 and 12 weeks, in the case of an attack or maintenance treatment.
- the unit dose may be more low, for example 2 or 5 mg.
- it may be effective to administer the drug first intravenously and then orally.
- the invention also has the advantage of allowing effective sequential treatment by simple administration of a single tablet dosed at 60 or 90 mg per week.
- One of the advantages of the present invention is to allow the treatment of the pathologies indicated above with a dosage limited to a single dose of drug per day, including in the treatment of duodenal ulcer resulting from infection by Helicobacter pylori , unlike conventional drugs, including conventional proton pump inhibitors which require two daily doses.
- An example of preparation of the (-) enantiomer of tenatoprazole is described below in order to illustrate the present invention.
- UV spectrum (methanol-water): ⁇ max : 272 n, 315 nm.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004564280A JP5230897B2 (ja) | 2002-12-16 | 2003-12-16 | テナトプラゾールの(−)鏡像体とその治療適用 |
KR1020137034689A KR20140022437A (ko) | 2002-12-16 | 2003-12-16 | 테나토프라졸의 (-) 거울상 이성질체 및 이를 의학 치료에 사용하는 방법 |
EP03814481A EP1572692A1 (fr) | 2002-12-16 | 2003-12-16 | Enantiomere (-) du tenatoprazole et son application en therapeutique |
BR0317328-3A BR0317328A (pt) | 2002-12-16 | 2003-12-16 | Composto, composição farmacêutica e utilização de (-) - tenatoprazol |
US10/507,485 US7034038B2 (en) | 2002-12-16 | 2003-12-16 | Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
CA2509899A CA2509899C (fr) | 2002-12-16 | 2003-12-16 | Enantiomere (-) du tenatoprazole et son application en therapeutique |
MXPA05006419A MXPA05006419A (es) | 2002-12-16 | 2003-12-16 | Enantiomero (-) de tenatoprazol y su aplicacion terapeutica. |
KR1020127004143A KR20120087886A (ko) | 2002-12-16 | 2003-12-16 | 테나토프라졸의 (-) 거울상 이성질체 및 이를 의학 치료에 사용하는 방법 |
AU2003300627A AU2003300627B2 (en) | 2002-12-16 | 2003-12-16 | Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
NZ540663A NZ540663A (en) | 2002-12-16 | 2003-12-16 | Enantiomer (-) of tenatoprazole and their use for the treatment of digestive diseases and conditions |
IL168782A IL168782A (en) | 2002-12-16 | 2005-05-25 | Enantiomer (-) of tenatoprazole and its therapeutic use |
NO20052798A NO331505B1 (no) | 2002-12-16 | 2005-06-09 | (-) Enantiomeren av tenatoprazol, farmasoytisk preparat inneholdende denne samt anvendelse av denne for fremstilling av medisinsk preparat for behandling av sykdom |
US11/344,212 US7652034B2 (en) | 2002-12-16 | 2006-02-01 | Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0215949A FR2848555B1 (fr) | 2002-12-16 | 2002-12-16 | Enantiomere(-)du tenatoprazole et son application en therapeutique |
FR02/15949 | 2002-12-16 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/344,212 Division US7652034B2 (en) | 2002-12-16 | 2006-02-01 | Enantiomer (-) of tenatoprazole and the therapeutic use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004060891A1 true WO2004060891A1 (fr) | 2004-07-22 |
Family
ID=32338855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/003746 WO2004060891A1 (fr) | 2002-12-16 | 2003-12-16 | Enantiomere (-) du tenatoprazole et son application en therapeutique |
Country Status (16)
Country | Link |
---|---|
US (2) | US7034038B2 (fr) |
EP (1) | EP1572692A1 (fr) |
JP (1) | JP5230897B2 (fr) |
KR (3) | KR20050088184A (fr) |
CN (1) | CN100345849C (fr) |
AU (1) | AU2003300627B2 (fr) |
BR (1) | BR0317328A (fr) |
CA (1) | CA2509899C (fr) |
FR (1) | FR2848555B1 (fr) |
IL (1) | IL168782A (fr) |
MX (1) | MXPA05006419A (fr) |
NO (1) | NO331505B1 (fr) |
NZ (1) | NZ540663A (fr) |
PL (1) | PL215162B1 (fr) |
RU (1) | RU2310652C2 (fr) |
WO (1) | WO2004060891A1 (fr) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2876101A1 (fr) * | 2004-10-05 | 2006-04-07 | Sidem Pharma Sa Sa | Procede de preparation enantioselective de derives de sulfoxydes |
WO2006043280A1 (fr) * | 2004-10-19 | 2006-04-27 | Council Of Scientific And Industrial Research | Sels de ténatoprazole et procédé de préparation desdits sels |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2845915B1 (fr) * | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
FR2845916B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine |
FR2845917B1 (fr) * | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
FR2848555B1 (fr) * | 2002-12-16 | 2006-07-28 | Negma Gild | Enantiomere(-)du tenatoprazole et son application en therapeutique |
WO2004074285A1 (fr) * | 2003-02-24 | 2004-09-02 | Mitsubishi Pharma Corporation | Enantiomere de tenatoprazole et son utilisation dans une therapie |
FR2871800B1 (fr) * | 2004-06-17 | 2006-08-25 | Sidem Pharma Sa Sa | Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique |
US20060089376A1 (en) * | 2004-10-27 | 2006-04-27 | Joshi Ramesh A | Tenatoprazole salts and process of preparation thereof |
CN101497623B (zh) * | 2008-01-30 | 2011-01-12 | 山东轩竹医药科技有限公司 | 含有咪唑并吡啶的化合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028558A1 (fr) * | 1999-10-22 | 2001-04-26 | Astrazeneca Ab | Formulations de benzimidazoles substitues |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
SE8204879D0 (sv) | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
JPH0643426B2 (ja) | 1986-07-25 | 1994-06-08 | 東京田辺製薬株式会社 | イミダゾ〔4,5−b〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤 |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
FR2845915B1 (fr) | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
FR2845916B1 (fr) | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine |
FR2845917B1 (fr) | 2002-10-21 | 2006-07-07 | Negma Gild | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire |
AU2003289948B2 (en) * | 2002-12-06 | 2009-12-24 | Takeda Gmbh | Process for preparing optically pure active compounds |
FR2848555B1 (fr) * | 2002-12-16 | 2006-07-28 | Negma Gild | Enantiomere(-)du tenatoprazole et son application en therapeutique |
-
2002
- 2002-12-16 FR FR0215949A patent/FR2848555B1/fr not_active Expired - Fee Related
-
2003
- 2003-12-16 KR KR1020057011100A patent/KR20050088184A/ko not_active Application Discontinuation
- 2003-12-16 RU RU2005122465/04A patent/RU2310652C2/ru not_active IP Right Cessation
- 2003-12-16 NZ NZ540663A patent/NZ540663A/en not_active IP Right Cessation
- 2003-12-16 KR KR1020137034689A patent/KR20140022437A/ko not_active Application Discontinuation
- 2003-12-16 US US10/507,485 patent/US7034038B2/en not_active Expired - Fee Related
- 2003-12-16 WO PCT/FR2003/003746 patent/WO2004060891A1/fr active Application Filing
- 2003-12-16 CN CNB2003801062679A patent/CN100345849C/zh not_active Expired - Fee Related
- 2003-12-16 MX MXPA05006419A patent/MXPA05006419A/es active IP Right Grant
- 2003-12-16 KR KR1020127004143A patent/KR20120087886A/ko not_active Application Discontinuation
- 2003-12-16 BR BR0317328-3A patent/BR0317328A/pt not_active IP Right Cessation
- 2003-12-16 AU AU2003300627A patent/AU2003300627B2/en not_active Ceased
- 2003-12-16 PL PL377738A patent/PL215162B1/pl not_active IP Right Cessation
- 2003-12-16 CA CA2509899A patent/CA2509899C/fr not_active Expired - Fee Related
- 2003-12-16 EP EP03814481A patent/EP1572692A1/fr not_active Withdrawn
- 2003-12-16 JP JP2004564280A patent/JP5230897B2/ja not_active Expired - Fee Related
-
2005
- 2005-05-25 IL IL168782A patent/IL168782A/en not_active IP Right Cessation
- 2005-06-09 NO NO20052798A patent/NO331505B1/no not_active IP Right Cessation
-
2006
- 2006-02-01 US US11/344,212 patent/US7652034B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028558A1 (fr) * | 1999-10-22 | 2001-04-26 | Astrazeneca Ab | Formulations de benzimidazoles substitues |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2876101A1 (fr) * | 2004-10-05 | 2006-04-07 | Sidem Pharma Sa Sa | Procede de preparation enantioselective de derives de sulfoxydes |
WO2006037894A1 (fr) * | 2004-10-05 | 2006-04-13 | Sidem Pharma S.A. | Procede de preparation enantioselective de derives de sulfoxydes. |
US7528251B2 (en) | 2004-10-05 | 2009-05-05 | Sidem Pharma Sa | Method for enantioselective preparation of sulphoxide derivatives |
AU2005291156B2 (en) * | 2004-10-05 | 2011-12-22 | Sidem Pharma S.A. | Method for enantioselective preparation of sulphoxide derivatives |
WO2006043280A1 (fr) * | 2004-10-19 | 2006-04-27 | Council Of Scientific And Industrial Research | Sels de ténatoprazole et procédé de préparation desdits sels |
Also Published As
Publication number | Publication date |
---|---|
BR0317328A (pt) | 2005-11-08 |
AU2003300627B2 (en) | 2009-07-23 |
FR2848555A1 (fr) | 2004-06-18 |
RU2005122465A (ru) | 2006-01-20 |
PL377738A1 (pl) | 2006-02-20 |
CN100345849C (zh) | 2007-10-31 |
KR20120087886A (ko) | 2012-08-07 |
US7652034B2 (en) | 2010-01-26 |
FR2848555B1 (fr) | 2006-07-28 |
KR20140022437A (ko) | 2014-02-24 |
US7034038B2 (en) | 2006-04-25 |
JP5230897B2 (ja) | 2013-07-10 |
PL215162B1 (pl) | 2013-10-31 |
JP2006513230A (ja) | 2006-04-20 |
US20060194832A1 (en) | 2006-08-31 |
NO331505B1 (no) | 2012-01-16 |
CN1726214A (zh) | 2006-01-25 |
MXPA05006419A (es) | 2006-03-08 |
RU2310652C2 (ru) | 2007-11-20 |
CA2509899C (fr) | 2012-07-03 |
KR20050088184A (ko) | 2005-09-02 |
CA2509899A1 (fr) | 2004-07-22 |
IL168782A (en) | 2013-05-30 |
US20050119298A1 (en) | 2005-06-02 |
EP1572692A1 (fr) | 2005-09-14 |
AU2003300627A1 (en) | 2004-07-29 |
NO20052798L (no) | 2005-07-04 |
NZ540663A (en) | 2007-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7652034B2 (en) | Enantiomer (-) of tenatoprazole and the therapeutic use thereof | |
WO2004087702A2 (fr) | Procede de preparation enantioselective de derives de sulfoxydes. | |
EP1664044B1 (fr) | Sel de sodium monohydrate du s-tenatoprazole et application en tant qu'inhibiteur de la pompe a protons | |
EP1802620B1 (fr) | Procede de preparation enantioselective de derives de sulfoxydes. | |
FR2893616A1 (fr) | Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant | |
WO1998025913A1 (fr) | Nouveaux derives [3h]-benzoxazole-2-thiones et [3h]-benzothiazole-2-thiones substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP2102202B1 (fr) | Conglomerats de sels de potassium du tenatoprazole | |
EP2838899B1 (fr) | Dérivés de thiazolidinedione, leur préparation et leur utilisation dans le traitement des cancers | |
WO2004037256A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine | |
FR2852956A1 (fr) | Procede de preparation enantioselective de derives de sulfoxydes | |
FR2863611A1 (fr) | Procede de preparation enantioselective de derives de sulfoxydes | |
FR2925899A1 (fr) | Procede de preparation enantioselective de sulfoxydes. | |
CA2634320A1 (fr) | Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2845087A1 (fr) | Nouveaux acides arylhexadienoiques substitues et leurs esters,utilisables dans le traitement et la prevention du diabete, des dyslipidemies,de l'atherosclerose, compositions pharmaceutiques les contenant et procedes de preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10507485 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 168782 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 377738 Country of ref document: PL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2472/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 540663 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2509899 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003300627 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/006419 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003814481 Country of ref document: EP Ref document number: 20038A62679 Country of ref document: CN Ref document number: 2004564280 Country of ref document: JP Ref document number: 1020057011100 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2005122465 Country of ref document: RU Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057011100 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003814481 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0317328 Country of ref document: BR |